Urology Times

12/17/2025

Topline results from KEYNOTE-B15: Perioperative EV/pembro yielded significant improvements in EFS, OS, and pCR rates vs neoadjuvant chemotherapy and surgery in cisplatin-eligible MIBC.

The combination yielded significant improvements in event-free survival, overall survival, and pathologic complete response rates vs neoadjuvant chemotherapy.

12/17/2025

If had a Spotify Wrapped… 🎧
Here are the karaoke songs urology KOLs are pressing repeat on 🎤
What’s your go-to?

12/16/2025

Data from the pivotal QUILT-3.032 trial have been published in the Journal of Urology, showing the safety and efficacy of nogapendekin alfa inbakicept plus BCG in patients with BCG-unresponsive high-grade papillary-only NMIBC.

The combination demonstrated a disease-specific survival rate of 98.7% at 12 months and 96.0% at 36 months.

12/16/2025

In this episode of First Assist, host Taylor Goodstein, MD, welcomes back Pretesh Patel, MD, for an in-depth discussion on the evolving role of radiation therapy across the spectrum of advanced prostate cancer.

This episode offers practical insights for clinicians navigating complex prostate cancer cases and underscores how precision imaging and tailored radiation strategies are redefining care for patients with advanced disease.

12/16/2025

The FDA has granted 510(k) clearance to an enhanced Revi wearable device for patients with urgency urinary incontinence.

The safety and efficacy of the Revi System were established in the pivotal OASIS trial.

12/15/2025

The FDA has approved flibanserin for hypoactive sexual desire disorder in postmenopausal women.

With this approval, flibanserin becomes the first and only treatment of its kind for women less than 65 years of age.

12/12/2025

The FDA has approved niraparib and abiraterone acetate plus prednisone for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer.

The approval is supported by data from the phase 3 AMPLITUDE trial.

12/12/2025

The FDA has approved oral zoliflodacin (Nuzolvence) for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 77 lbs.

In a phase 3 trial, zoliflodacin demonstrated non-inferior efficacy compared with ceftriaxone plus azithromycin.

12/12/2025

WATCH 🎥: Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.

Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.

12/11/2025

Watch our expert-led presentation to learn more about GEMTESA® (vibegron). David Staskin, MD and Kevin McVary, MD, FACS will cover key clinical insights, including data from the phase 3 COURAGE trial and provide a firsthand patient perspective. Don’t miss this opportunity to learn more! Watch now: bit.ly/3UG4OMF Please see full Prescribing Information. bit.ly/4fhyJEt

12/11/2025

The FDA has approved gepotidacin (Blujepa) as an oral treatment for uncomplicated urogenital gonorrhea in patients 12 years of age and older.

The approval is supported by data from the phase 3 EAGLE-1 trial.

12/11/2025

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Emad Ibrahim, MD, HCLD, to discuss the fertility & sexual health challenges men face after spinal cord injury.

Ibrahim explains the unique challenges men face after spinal cord injury, including neurogenic erectile dysfunction, ejaculatory dysfunction, and particularly the distinctive s***m abnormalities seen in this population.